Hydrazide-containing CFTR inhibitor compounds and uses thereof
    1.
    发明授权
    Hydrazide-containing CFTR inhibitor compounds and uses thereof 有权
    含酰肼的CFTR抑制剂化合物及其用途

    公开(公告)号:US07888332B2

    公开(公告)日:2011-02-15

    申请号:US12175982

    申请日:2008-07-18

    IPC分类号: A01N43/04 A61K31/715

    摘要: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a hydrazide-containing compound to a non-human animal in an amount sufficient to inhibit CFTR.

    摘要翻译: 本发明提供用于抑制囊性纤维化跨膜传导调节蛋白(CFTR)的组合物,药物制剂和方法,其可用于研究和治疗CFTR介导的疾病和病症。 本发明的组合物和药物制剂可以包含一种或多种含酰肼的化合物,并且还可以包含一种或多种药学上可接受的载体,赋形剂和/或佐剂。 在某些实施方案中,本发明的方法包括给予患有CFTR介导的疾病或病症的患者,有效量的含酰肼的化合物。 在其它实施方案中,本发明提供了抑制CFTR的方法,其包括使受试者中的细胞与有效量的含酰肼化合物接触。 此外,本发明的特征在于CFTR介导的疾病的非人动物模型,其通过以足以抑制CFTR的量向非人动物施用含酰肼的化合物来产生该模型。

    Hydrazide-containing CFTR inhibitor compounds and uses thereof
    2.
    发明授权
    Hydrazide-containing CFTR inhibitor compounds and uses thereof 有权
    含酰肼的CFTR抑制剂化合物及其用途

    公开(公告)号:US07414037B2

    公开(公告)日:2008-08-19

    申请号:US11093749

    申请日:2005-03-29

    IPC分类号: A01N43/04 A61K31/715

    摘要: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a hydrazide-containing compound to a non-human animal in an amount sufficient to inhibit CFTR.

    摘要翻译: 本发明提供用于抑制囊性纤维化跨膜传导调节蛋白(CFTR)的组合物,药物制剂和方法,其可用于研究和治疗CFTR介导的疾病和病症。 本发明的组合物和药物制剂可以包含一种或多种含酰肼的化合物,并且还可以包含一种或多种药学上可接受的载体,赋形剂和/或佐剂。 在某些实施方案中,本发明的方法包括给予患有CFTR介导的疾病或病症的患者,有效量的含酰肼的化合物。 在其它实施方案中,本发明提供了抑制CFTR的方法,其包括使受试者中的细胞与有效量的含酰肼化合物接触。 此外,本发明的特征在于CFTR介导的疾病的非人动物模型,其通过以足以抑制CFTR的量向非人动物施用含酰肼的化合物来产生该模型。

    HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF
    3.
    发明申请
    HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF 有权
    含有含氟化物的CFTR抑制剂化合物及其用途

    公开(公告)号:US20090048207A1

    公开(公告)日:2009-02-19

    申请号:US12175982

    申请日:2008-07-18

    摘要: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a hydrazide-containing compound to a non-human animal in an amount sufficient to inhibit CFTR.

    摘要翻译: 本发明提供用于抑制囊性纤维化跨膜传导调节蛋白(CFTR)的组合物,药物制剂和方法,其可用于研究和治疗CFTR介导的疾病和病症。 本发明的组合物和药物制剂可以包含一种或多种含酰肼的化合物,并且还可以包含一种或多种药学上可接受的载体,赋形剂和/或佐剂。 在某些实施方案中,本发明的方法包括给予患有CFTR介导的疾病或病症的患者,有效量的含酰肼的化合物。 在其它实施方案中,本发明提供了抑制CFTR的方法,其包括使受试者中的细胞与有效量的含酰肼化合物接触。 此外,本发明的特征在于CFTR介导的疾病的非人动物模型,其通过以足以抑制CFTR的量向非人动物施用含酰肼的化合物来产生该模型。

    Hydrazide-containing CFTR inhibitor compounds and uses thereof
    4.
    发明申请
    Hydrazide-containing CFTR inhibitor compounds and uses thereof 有权
    含酰肼的CFTR抑制剂化合物及其用途

    公开(公告)号:US20050239740A1

    公开(公告)日:2005-10-27

    申请号:US11093749

    申请日:2005-03-29

    摘要: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a hydrazide-containing compound to a non-human animal in an amount sufficient to inhibit CFTR.

    摘要翻译: 本发明提供用于抑制囊性纤维化跨膜传导调节蛋白(CFTR)的组合物,药物制剂和方法,其可用于研究和治疗CFTR介导的疾病和病症。 本发明的组合物和药物制剂可以包含一种或多种含酰肼的化合物,并且还可以包含一种或多种药学上可接受的载体,赋形剂和/或佐剂。 在某些实施方案中,本发明的方法包括给予患有CFTR介导的疾病或病症的患者,有效量的含酰肼的化合物。 在其它实施方案中,本发明提供了抑制CFTR的方法,其包括使受试者中的细胞与有效量的含酰肼化合物接触。 此外,本发明的特征在于CFTR介导的疾病的非人动物模型,其通过以足以抑制CFTR的量向非人动物施用含酰肼的化合物来产生该模型。

    HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF
    5.
    发明申请
    HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF 审中-公开
    含有含氟化物的CFTR抑制剂化合物及其用途

    公开(公告)号:US20110119775A1

    公开(公告)日:2011-05-19

    申请号:US13011626

    申请日:2011-01-21

    摘要: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a hydrazide-containing compound to a non-human animal in an amount sufficient to inhibit CFTR.

    摘要翻译: 本发明提供用于抑制囊性纤维化跨膜传导调节蛋白(CFTR)的组合物,药物制剂和方法,其可用于研究和治疗CFTR介导的疾病和病症。 本发明的组合物和药物制剂可以包含一种或多种含酰肼的化合物,并且还可以包含一种或多种药学上可接受的载体,赋形剂和/或佐剂。 在某些实施方案中,本发明的方法包括给予患有CFTR介导的疾病或病症的患者,有效量的含酰肼的化合物。 在其它实施方案中,本发明提供了抑制CFTR的方法,其包括使受试者中的细胞与有效量的含酰肼化合物接触。 此外,本发明的特征在于CFTR介导的疾病的非人动物模型,其通过以足以抑制CFTR的量向非人动物施用含酰肼的化合物来产生该模型。